Mr. Speaker, the promotional practices used by the drug companies to curry favour with health professionals and pharmacists cost a fortune. It might prove highly beneficial to limit drug prices and monitor such practices.
Does the minister plan to follow our recommendation and look into the possibility of providing a framework for the promotional practices of drug companies?